Knowledge HQ

This study improved EBV-specific T cell manufacturing using GMP reagents and G-Rex. G-Rex100 yielded higher CD8+ T cell percentages and expansion compared to standard flasks. Detailed cytokine profiling characterized the product phenotype.

This study found that exercise mobilizes SARS-CoV-2 specific T-cells and antibodies. To assess T-cell function, SARS-CoV-2 virus-specific T-cells were expanded ex vivo from PBMCs using gas-permeable G-Rex devices for 7 days.

This paper details a manufacturing process for NKG2D CAR-T cells using piggyBac vectors and K562 aAPCs. It demonstrates robust expansion and cytotoxicity. While the specific protocol uses T75 flasks, it cites previous work utilizing G-Rex vessels for large-scale T cell expansion.

This poster describes a modular, closed CAR-T manufacturing platform. It details expansion strategies using G-Rex 100MCS for low doses and a two-step process with G-Rex 500MCS for high doses, consistently achieving high cell viability and yields.

This article reports a superior method for expanding NK and CAR-NK cells using 221-mIL-21 feeder cells. The expanded cells showed enhanced cytotoxicity and metabolic function. G-Rex 6 multi-well plates were utilized for the culture and maintenance of the expanding NK cells.

This study demonstrates that anti-CD147 CAR-T and CAR-NK cells effectively kill hepatocellular carcinoma cells. To minimize toxicity, a logic-gated GPC3-synNotch system was developed. Transduced NK cells were maintained and expanded in G-Rex 6 multi-well cell culture plates with IL-2.

This study developed a GMP-compliant protocol for expanding CIK cells using G-Rex gas-permeable. G-Rex6 well plates yielded superior expansion and cytotoxicity compared to standard or G-Rex6M, achieving 400-fold expansion with minimal manipulation.

This study uses targeted scRNA-seq and protein analysis to characterize human CD4+ T cells. It identifies CD80 and CD86 as markers of activated Tregs. Tregs were expanded in G-Rex, confirming that activation induces B7 molecule expression, revealing new insights into Treg biology and heterogeneity.

This study evaluates the efficacy of intracerebroventricular (i.c.v.) delivery of piggyBac CD19 CAR T cells for CNS ALL. I.c.v. delivery eliminated CNS leukemia in mice, whereas intravenous delivery had only partial effects. The study supports direct CNS delivery as a potential therapeutic strategy.

This study reports the preclinical validation of ISIKOK-19 CD19 CAR-T cells for a Turkish clinical trial. Using G-Rex 100M for expansion and BX-795 to enhance transduction, researchers produced effective CAR-T cells that eliminated tumors in vivo, demonstrating a robust and cost-effective manufacturing process.

This study presents a bifunctional fusion protein combining anti-PD-1 antibody with an engineered IL-21 mutein. Using G-Rex for cell culture, the fusion protein demonstrated targeted IL-21 delivery to PD-1+ T cells, enhancing cytotoxicity and tumor control in mice while minimizing off-target effects.

This study evaluates allogeneic FLT3 CAR T cells with a safety off-switch for AML. Expanded in G-Rex plates, these cells showed potent antileukemic activity. The off-switch allowed depletion of CAR T cells to mitigate myelotoxicity and enable bone marrow recovery, supporting clinical development.